Efficacy and safety of risankizumab for active psoriatic arthritis: 100-week results from the Phase 3 KEEPsAKE1 randomized clinical trial
Rheumatol Ther 2024 doi: 10.1007/s40744-024-00654-5 Epub ahead of print
Risankizumab therapy was associated with significant and sustained improvement in multiple disease domains from Week 52 through Week 100, compared with placebo. Kristensen et al. investigated the safety, efficacy and tolerability of 100-week risankizumab therapy in PsA patients with previous inadequate response to ≥1 csDMARD, using data from KEEPsAKE 1 trial.
Significantly more patients receiving risankizumab achieved the primary endpoint of ACR20 response at Week 24 compared with placebo. Risankizumab was generally well tolerated and the long-term exposure-adjusted event rate of any TEAEs decreased compared with Week 24. The KEEPsAKE studies remain ongoing to report on continued efficacy and safety.
Keywords:
